ReP USP - Resultado da busca

Artigo de periodico
Prognostic impact of primary tumor sidedness in stage III colorectal cancer: real-world evidence from a Brazilian Cohort (2024)
Protasio, Bruno Medonca; Castria, Tiago Biachi de; Natalino, Renato; Mangone, Flavia R; Saragiotto, Daniel Fernandes; Sabbaga, Jorge; Hoff, Paulo Marcelo Gehm ; Chammas, Roger
Fonte: Clinical colorectal cancer. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, NEOPLASIAS DO COLON, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTASIO, Bruno Medonca et al. Prognostic impact of primary tumor sidedness in stage III colorectal cancer: real-world evidence from a Brazilian Cohort. Clinical colorectal cancer, v. 23, n. 1, p. 73-84, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/76894. Acesso em: 25 out. 2025.
APA
Protasio, B. M., Castria, T. B. de, Natalino, R., Mangone, F. R., Saragiotto, D. F., Sabbaga, J., et al. (2024). Prognostic impact of primary tumor sidedness in stage III colorectal cancer: real-world evidence from a Brazilian Cohort. Clinical colorectal cancer, 23( 1), 73-84. doi:10.1016/j.clcc.2023.12.001
NLM
Protasio BM, Castria TB de, Natalino R, Mangone FR, Saragiotto DF, Sabbaga J, Hoff PMG, Chammas R. Prognostic impact of primary tumor sidedness in stage III colorectal cancer: real-world evidence from a Brazilian Cohort [Internet]. Clinical colorectal cancer. 2024 ; 23( 1): 73-84.[citado 2025 out. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76894
Vancouver
Protasio BM, Castria TB de, Natalino R, Mangone FR, Saragiotto DF, Sabbaga J, Hoff PMG, Chammas R. Prognostic impact of primary tumor sidedness in stage III colorectal cancer: real-world evidence from a Brazilian Cohort [Internet]. Clinical colorectal cancer. 2024 ; 23( 1): 73-84.[citado 2025 out. 25 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76894
Artigo de periodico
Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer - Who Are These Patients? (2021)
Bonadio, Renata Colombo; Freitas, Guilherme Fialho; Batista, Daniel Negrini; Moreira, Otavio Augusto Noschang; Dias, Carla A. R.; Castria, Tiago Biachi; Sabbaga, Jorge; Hoff, Paulo Marcelo Gehm
Fonte: Clinical colorectal cancer. Unidade: FM
Assuntos: QUIMIOTERAPIA ADJUVANTE, NEOPLASIAS DOS GENITAIS FEMININOS, RADIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BONADIO, Renata Colombo et al. Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer - Who Are These Patients?. Clinical colorectal cancer, v. 20, n. 3, p. E195-E200, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2021.04.002. Acesso em: 25 out. 2025.
APA
Bonadio, R. C., Freitas, G. F., Batista, D. N., Moreira, O. A. N., Dias, C. A. R., Castria, T. B., et al. (2021). Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer - Who Are These Patients? Clinical colorectal cancer, 20( 3), E195-E200. doi:10.1016/j.clcc.2021.04.002
NLM
Bonadio RC, Freitas GF, Batista DN, Moreira OAN, Dias CAR, Castria TB, Sabbaga J, Hoff PMG. Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer - Who Are These Patients? [Internet]. Clinical colorectal cancer. 2021 ; 20( 3): E195-E200.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2021.04.002
Vancouver
Bonadio RC, Freitas GF, Batista DN, Moreira OAN, Dias CAR, Castria TB, Sabbaga J, Hoff PMG. Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer - Who Are These Patients? [Internet]. Clinical colorectal cancer. 2021 ; 20( 3): E195-E200.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2021.04.002
Artigo de periodico-carta/editorial
Response to Comment on ""Organ Preservation for cT2N0 Distal Rectal Cancer-Are There Any Better Surgical Alternatives Without Chemoradiation?'' [Carta] (2019)
Gama, Angelita Habr ; Juliao, Guilherme P. Sao; Vailati, Bruna B; Fernandez, Laura M; Araujo, Sergio E. A; Sabbaga, Jorge; Aguilar, Patricia B; Perez, Rodrigo O
Fonte: Annals of surgery. Unidade: FM
Assuntos: NEOPLASIAS RETAIS, PRESERVAÇÃO DE TECIDO, QUIMIOTERAPIA ADJUVANTE, RADIOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GAMA, Angelita Habr et al. Response to Comment on ""Organ Preservation for cT2N0 Distal Rectal Cancer-Are There Any Better Surgical Alternatives Without Chemoradiation?'' [Carta]. Annals of surgery. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/SLA.0000000000003354. Acesso em: 25 out. 2025. , 2019
APA
Gama, A. H., Juliao, G. P. S., Vailati, B. B., Fernandez, L. M., Araujo, S. E. A., Sabbaga, J., et al. (2019). Response to Comment on ""Organ Preservation for cT2N0 Distal Rectal Cancer-Are There Any Better Surgical Alternatives Without Chemoradiation?'' [Carta]. Annals of surgery. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1097/SLA.0000000000003354
NLM
Gama AH, Juliao GPS, Vailati BB, Fernandez LM, Araujo SEA, Sabbaga J, Aguilar PB, Perez RO. Response to Comment on ""Organ Preservation for cT2N0 Distal Rectal Cancer-Are There Any Better Surgical Alternatives Without Chemoradiation?'' [Carta] [Internet]. Annals of surgery. 2019 ; 270( 6): E119-E120.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/SLA.0000000000003354
Vancouver
Gama AH, Juliao GPS, Vailati BB, Fernandez LM, Araujo SEA, Sabbaga J, Aguilar PB, Perez RO. Response to Comment on ""Organ Preservation for cT2N0 Distal Rectal Cancer-Are There Any Better Surgical Alternatives Without Chemoradiation?'' [Carta] [Internet]. Annals of surgery. 2019 ; 270( 6): E119-E120.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/SLA.0000000000003354
Artigo de periodico
Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy the impact of radiation therapy dose-escalation and consolidation chemotherapy (2019)
Habr Gama, Angelita; Juliao, Guilherme Pagin Sao; Vailati, Bruna Borba; Sabbaga, Jorge; Aguilar, Patricia Bailao; Fernandez, Laura Melina; Araujo, Sergio Eduardo Alonso; Perez, Rodrigo Oliva
Fonte: Annals of surgery. Unidade: FM
Assuntos: NEOPLASIAS RETAIS, QUIMIOTERAPIA, RADIOTERAPIA, PRESERVAÇÃO DE TECIDO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HABR GAMA, Angelita et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy the impact of radiation therapy dose-escalation and consolidation chemotherapy. Annals of surgery, v. 269, n. 1, p. 102-107, 2019Tradução . . Disponível em: https://doi.org/10.1097/SLA.0000000000002447. Acesso em: 25 out. 2025.
APA
Habr Gama, A., Juliao, G. P. S., Vailati, B. B., Sabbaga, J., Aguilar, P. B., Fernandez, L. M., et al. (2019). Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy the impact of radiation therapy dose-escalation and consolidation chemotherapy. Annals of surgery, 269( 1), 102-107. doi:10.1097/SLA.0000000000002447
NLM
Habr Gama A, Juliao GPS, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, Araujo SEA, Perez RO. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy the impact of radiation therapy dose-escalation and consolidation chemotherapy [Internet]. Annals of surgery. 2019 ; 269( 1): 102-107.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/SLA.0000000000002447
Vancouver
Habr Gama A, Juliao GPS, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, Araujo SEA, Perez RO. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy the impact of radiation therapy dose-escalation and consolidation chemotherapy [Internet]. Annals of surgery. 2019 ; 269( 1): 102-107.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/SLA.0000000000002447
Trabalho de evento-resumo periodico
Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30 (2019)
Santana, E; Costa, F P; Setogute, Y; Carvalho, L; Lima, P; Sousa, M; Gunz, B; Azevedo, F.; Sabbaga, Jorge; Santos, M; Biachi, T; Jardim, D; Freitas, D; Horvat, N; Otaviano, R; Testagrossa, Leonardo; Iemma, Antônio Francisco; Silva, Flávio Soares Corrêa da ; Tuszynski, Jack
Fonte: Annals of Oncology. Nome do evento: European Society for Medical Oncology Congress - ESMO. Unidades: IME, ESALQ
Assunto: ONCOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTANA, E et al. Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30. Annals of Oncology. Amsterdam: Elsevier. Disponível em: https://doi.org/10.1093/annonc/mdz261.006. Acesso em: 25 out. 2025. , 2019
APA
Santana, E., Costa, F. P., Setogute, Y., Carvalho, L., Lima, P., Sousa, M., et al. (2019). Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30. Annals of Oncology. Amsterdam: Elsevier. doi:10.1093/annonc/mdz261.006
NLM
Santana E, Costa FP, Setogute Y, Carvalho L, Lima P, Sousa M, Gunz B, Azevedo F, Sabbaga J, Santos M, Biachi T, Jardim D, Freitas D, Horvat N, Otaviano R, Testagrossa L, Iemma AF, Silva FSC da, Tuszynski J. Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30 [Internet]. Annals of Oncology. 2019 ; 30 v663.[citado 2025 out. 25 ] Available from: https://doi.org/10.1093/annonc/mdz261.006
Vancouver
Santana E, Costa FP, Setogute Y, Carvalho L, Lima P, Sousa M, Gunz B, Azevedo F, Sabbaga J, Santos M, Biachi T, Jardim D, Freitas D, Horvat N, Otaviano R, Testagrossa L, Iemma AF, Silva FSC da, Tuszynski J. Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30 [Internet]. Annals of Oncology. 2019 ; 30 v663.[citado 2025 out. 25 ] Available from: https://doi.org/10.1093/annonc/mdz261.006
Artigo de periodico
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib (2018)
Fonseca, Leonardo Gomes da; Carrilho, Flair Jose; Hoff, Paulo Marcelo; Marta, Guilherme Nader; Braghiroli, Maria Ignez Freitas Melro; Chagas, Aline Lopes; Sabbaga, Jorge
Fonte: Bmc cancer. Unidade: FM
Assuntos: CARCINOMA HEPATOCELULAR, CITOTOXINAS, INIBIDORES DE ENZIMAS, TAXA DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes da et al. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. Bmc cancer, v. 18, 2018Tradução . . Disponível em: https://doi.org/10.1186/s12885-018-5173-0. Acesso em: 25 out. 2025.
APA
Fonseca, L. G. da, Carrilho, F. J., Hoff, P. M., Marta, G. N., Braghiroli, M. I. F. M., Chagas, A. L., & Sabbaga, J. (2018). Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib. Bmc cancer, 18. doi:10.1186/s12885-018-5173-0
NLM
Fonseca LG da, Carrilho FJ, Hoff PM, Marta GN, Braghiroli MIFM, Chagas AL, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib [Internet]. Bmc cancer. 2018 ; 18[citado 2025 out. 25 ] Available from: https://doi.org/10.1186/s12885-018-5173-0
Vancouver
Fonseca LG da, Carrilho FJ, Hoff PM, Marta GN, Braghiroli MIFM, Chagas AL, Sabbaga J. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib [Internet]. Bmc cancer. 2018 ; 18[citado 2025 out. 25 ] Available from: https://doi.org/10.1186/s12885-018-5173-0
Artigo de periodico
Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community (2017)
Protásio, Bruno Mendonça; Matutino, Adriana; Lage, Liana Valente; Santana, Iuri; Ramos, Ricardo; Sabbaga, Jorge; Capareli, Fernanda; Saragiotto, Daniel; Riechelmann, Rachel P.; Hoff, Paulo M.
Fonte: Clinical Colorectal Cancer. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, QUIMIOTERAPIA ADJUVANTE, ANTINEOPLÁSICOS, AVANÇO DA DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTÁSIO, Bruno Mendonça et al. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, v. 16, n. 1, p. 65-72, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2016.07.001. Acesso em: 25 out. 2025.
APA
Protásio, B. M., Matutino, A., Lage, L. V., Santana, I., Ramos, R., Sabbaga, J., et al. (2017). Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community. Clinical Colorectal Cancer, 16( 1), 65-72. doi:10.1016/j.clcc.2016.07.001
NLM
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001
Vancouver
Protásio BM, Matutino A, Lage LV, Santana I, Ramos R, Sabbaga J, Capareli F, Saragiotto D, Riechelmann RP, Hoff PM. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community [Internet]. Clinical Colorectal Cancer. 2017 ; 16( 1): 65-72.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2016.07.001
Trabalho de evento-resumo periodico
Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer (2016)
Pereira, Guilherme Luiz Stelko; Fonseca, Leonardo Gomes da; Ramos, Marcus Fernando Kodama Pertille; Ribeiro Júnior, Ulysses; Pereira, Gabriel; Pereira, Marina Alessandra; Mello, Evandro Sobroza de; Sabbaga, Jorge; Hoff, Paulo Marcelo Gehm
Fonte: Journal of clinical oncology. Unidade: FM
Assuntos: NEOPLASIAS GÁSTRICAS, METÁSTASE NEOPLÁSICA, PROCEDIMENTOS CIRÚRGICOS DO SISTEMA DIGESTÓRIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA, Guilherme Luiz Stelko et al. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer. Journal of clinical oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meetinglibrary.asco.org/content/159941-173. Acesso em: 25 out. 2025. , 2016
APA
Pereira, G. L. S., Fonseca, L. G. da, Ramos, M. F. K. P., Ribeiro Júnior, U., Pereira, G., Pereira, M. A., et al. (2016). Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer. Journal of clinical oncology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meetinglibrary.asco.org/content/159941-173
NLM
Pereira GLS, Fonseca LG da, Ramos MFKP, Ribeiro Júnior U, Pereira G, Pereira MA, Mello ES de, Sabbaga J, Hoff PMG. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer [Internet]. Journal of clinical oncology. 2016 ; 34( 04): su01.[citado 2025 out. 25 ] Available from: http://meetinglibrary.asco.org/content/159941-173
Vancouver
Pereira GLS, Fonseca LG da, Ramos MFKP, Ribeiro Júnior U, Pereira G, Pereira MA, Mello ES de, Sabbaga J, Hoff PMG. Prospective results of perioperative chemotherapy (PCT) with cisplatia and irinotecan for locally advanced gastric cancer [Internet]. Journal of clinical oncology. 2016 ; 34( 04): su01.[citado 2025 out. 25 ] Available from: http://meetinglibrary.asco.org/content/159941-173
Trabalho de evento-resumo periodico
Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community (2015)
Protasio, Bruno Mendonca; Matutino, Adriana Reis Brandao; Lage, Liana Valente; De Santana, Iuri Amorim; Ramos, Ricardo Emanuel De Oliveira; Caires-Lima, Rafael; Caires, Inacelli Queiroz De Souza; Riechelmann, Rachel Pimenta; Saragiotto, Daniel Fernandes; Sabbaga, Jorge; Hoff, Paulo Marcelo
Fonte: Journal of Clinical Oncology. Nome do evento: Gastrointestinal Cancers Symposium. Unidade: FM
Assuntos: QUIMIOTERAPIA (EFEITOS ADVERSOS), NEOPLASIAS COLORRETAIS (TERAPIA), TOXICIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PROTASIO, Bruno Mendonca et al. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b. Acesso em: 25 out. 2025. , 2015
APA
Protasio, B. M., Matutino, A. R. B., Lage, L. V., De Santana, I. A., Ramos, R. E. D. O., Caires-Lima, R., et al. (2015). Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
NLM
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2025 out. 25 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
Vancouver
Protasio BM, Matutino ARB, Lage LV, De Santana IA, Ramos REDO, Caires-Lima R, Caires IQDS, Riechelmann RP, Saragiotto DF, Sabbaga J, Hoff PM. Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2025 out. 25 ] Available from: http://meeting.ascopubs.org/cgi/content/abstract/33/3_suppl/760?sid=58f206fe-c1f4-43bf-bb03-b609e9edf49b
Artigo de periodico
The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 (2015)
Teixeira, Marcela Crosara; Marques, Daniel Fernandes; Ferrari, Anezka Celis; Alves, Michel Fabiano Silva; Alex, Alexandra Khichfy; Sabbaga, Jorge; Hoff, Paulo M.; Riechelmann, Rachel P.
Fonte: Clinical Colorectal Cancer. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS (QUIMIOTERAPIA), METÁSTASE NEOPLÁSICA, CUIDADOS PALIATIVOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. Clinical Colorectal Cancer, v. 14, n. 1, p. 52-57, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.clcc.2014.09.010. Acesso em: 25 out. 2025.
APA
Teixeira, M. C., Marques, D. F., Ferrari, A. C., Alves, M. F. S., Alex, A. K., Sabbaga, J., et al. (2015). The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. Clinical Colorectal Cancer, 14( 1), 52-57. doi:10.1016/j.clcc.2014.09.010
NLM
Teixeira MC, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 [Internet]. Clinical Colorectal Cancer. 2015 ; 14( 1): 52-57.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2014.09.010
Vancouver
Teixeira MC, Marques DF, Ferrari AC, Alves MFS, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 [Internet]. Clinical Colorectal Cancer. 2015 ; 14( 1): 52-57.[citado 2025 out. 25 ] Available from: https://doi.org/10.1016/j.clcc.2014.09.010
Artigo de periodico
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation (2015)
Carpinetti, Paola; Donnard, Elisa; Bettoni, Fabiana; Asprino, Paula; Koyama, Fernanda; Rozanski, Andrei; Sabbaga, Jorge; Habr-Gama, Angelita; Parmigiani, Raphael B.; Galante, Pedro A. F.; Perez, Rodrigo O.; Camargo, Anamaria A.
Fonte: Oncotarget. Unidade: FM
Assuntos: NEOPLASIAS RETAIS (CIRURGIA), BIÓPSIA, QUIMIOTERAPIA ADJUVANTE, MONITORIZAÇÃO FISIOLÓGICA, BIOMARCADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARPINETTI, Paola et al. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget, v. 6, n. 35, p. 38360-38371, 2015Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.5256. Acesso em: 25 out. 2025.
APA
Carpinetti, P., Donnard, E., Bettoni, F., Asprino, P., Koyama, F., Rozanski, A., et al. (2015). The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget, 6( 35), 38360-38371. doi:10.18632/oncotarget.5256
NLM
Carpinetti P, Donnard E, Bettoni F, Asprino P, Koyama F, Rozanski A, Sabbaga J, Habr-Gama A, Parmigiani RB, Galante PAF, Perez RO, Camargo AA. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation [Internet]. Oncotarget. 2015 ; 6( 35): 38360-38371.[citado 2025 out. 25 ] Available from: https://doi.org/10.18632/oncotarget.5256
Vancouver
Carpinetti P, Donnard E, Bettoni F, Asprino P, Koyama F, Rozanski A, Sabbaga J, Habr-Gama A, Parmigiani RB, Galante PAF, Perez RO, Camargo AA. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation [Internet]. Oncotarget. 2015 ; 6( 35): 38360-38371.[citado 2025 out. 25 ] Available from: https://doi.org/10.18632/oncotarget.5256
Artigo de periodico
Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma (2015)
Fonseca, Leonardo Gomes Da; Barroso-sousa, Romualdo; Bento, Afonso Da Silva Alves; Blanco, Bruna Paccola; Valente, Gabriel Luis; Pfiffer, Tulio Eduardo Flesch; Hoff, Paulo Marcelo; Sabbaga, Jorge
Fonte: Molecular and clinical oncology. Unidade: FM
Assuntos: CARCINOMA HEPATOCELULAR, INIBIDORES DE ENZIMAS, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes Da et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and clinical oncology, v. 3, n. 4, p. 793-796, 2015Tradução . . Disponível em: https://doi.org/10.3892/mco.2015.536. Acesso em: 25 out. 2025.
APA
Fonseca, L. G. D., Barroso-sousa, R., Bento, A. D. S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2015). Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. Molecular and clinical oncology, 3( 4), 793-796. doi:10.3892/mco.2015.536
NLM
Fonseca LGD, Barroso-sousa R, Bento ADSA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma [Internet]. Molecular and clinical oncology. 2015 ; 3( 4): 793-796.[citado 2025 out. 25 ] Available from: https://doi.org/10.3892/mco.2015.536
Vancouver
Fonseca LGD, Barroso-sousa R, Bento ADSA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma [Internet]. Molecular and clinical oncology. 2015 ; 3( 4): 793-796.[citado 2025 out. 25 ] Available from: https://doi.org/10.3892/mco.2015.536
Artigo de periodico
Is surgery always necessary in rectal cancer? (2014)
Sabbaga, Jorge; Braghiroli, Maria Ignez; Hoff, Paulo M.
Fonte: Oncology. Unidade: FM
Assuntos: NEOPLASIAS RETAIS (CIRURGIA;QUIMIOTERAPIA), PROCEDIMENTOS CIRÚRGICOS OPERATÓRIOS, TERAPIA COMBINADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABBAGA, Jorge e BRAGHIROLI, Maria Ignez e HOFF, Paulo M. Is surgery always necessary in rectal cancer?. Oncology, v. 28, n. 7, p. 607-611, 2014Tradução . . Disponível em: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer. Acesso em: 25 out. 2025.
APA
Sabbaga, J., Braghiroli, M. I., & Hoff, P. M. (2014). Is surgery always necessary in rectal cancer? Oncology, 28( 7), 607-611. Recuperado de http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
NLM
Sabbaga J, Braghiroli MI, Hoff PM. Is surgery always necessary in rectal cancer? [Internet]. Oncology. 2014 ; 28( 7): 607-611.[citado 2025 out. 25 ] Available from: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
Vancouver
Sabbaga J, Braghiroli MI, Hoff PM. Is surgery always necessary in rectal cancer? [Internet]. Oncology. 2014 ; 28( 7): 607-611.[citado 2025 out. 25 ] Available from: http://www.cancernetwork.com/oncology-journal/surgery-always-necessary-rectal-cancer
Artigo de periodico
Primary prevention of colorectal cancer: Myth or reality? (2014)
Teixeira, Marcela Crosara; Braghiroli, Maria Ignez; Sabbaga, Jorge; Hoff, Paulo M.
Fonte: World Journal of Gastroenterology. Unidade: FM
Assuntos: NUTRIÇÃO, NEOPLASIAS COLORRETAIS, ATIVIDADE FÍSICA, PREVENÇÃO PRIMÁRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TEIXEIRA, Marcela Crosara et al. Primary prevention of colorectal cancer: Myth or reality?. World Journal of Gastroenterology, v. 20, n. 41, p. 15060-15069, 2014Tradução . . Disponível em: https://doi.org/10.3748/wjg.v20.i41.15060. Acesso em: 25 out. 2025.
APA
Teixeira, M. C., Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2014). Primary prevention of colorectal cancer: Myth or reality? World Journal of Gastroenterology, 20( 41), 15060-15069. doi:10.3748/wjg.v20.i41.15060
NLM
Teixeira MC, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: Myth or reality? [Internet]. World Journal of Gastroenterology. 2014 ; 20( 41): 15060-15069.[citado 2025 out. 25 ] Available from: https://doi.org/10.3748/wjg.v20.i41.15060
Vancouver
Teixeira MC, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: Myth or reality? [Internet]. World Journal of Gastroenterology. 2014 ; 20( 41): 15060-15069.[citado 2025 out. 25 ] Available from: https://doi.org/10.3748/wjg.v20.i41.15060
Artigo de periodico
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib (2014)
Fonseca, Leonardo Gomes da; Barroso-Sousa, Romulado; Bento, Afonso da Silva Alves; Blanco, Bruna Paccola; Valente, Gabriel Luis; Pfiffer, Tulio Eduardo Flesch; Hoff, Paulo Marcelo; Sabbaga, Jorge
Fonte: Medical Oncology. Unidade: FM
Assuntos: NEOPLASIAS HEPÁTICAS (TERAPIA), TAXA DE SOBREVIVÊNCIA, PROGNÓSTICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FONSECA, Leonardo Gomes da et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, v. 31, p. 1-6, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0264-5. Acesso em: 25 out. 2025.
APA
Fonseca, L. G. da, Barroso-Sousa, R., Bento, A. da S. A., Blanco, B. P., Valente, G. L., Pfiffer, T. E. F., et al. (2014). Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Medical Oncology, 31, 1-6. doi:10.1007/s12032-014-0264-5
NLM
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2025 out. 25 ] Available from: https://doi.org/10.1007/s12032-014-0264-5
Vancouver
Fonseca LG da, Barroso-Sousa R, Bento A da SA, Blanco BP, Valente GL, Pfiffer TEF, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib [Internet]. Medical Oncology. 2014 ; 31 1-6.[citado 2025 out. 25 ] Available from: https://doi.org/10.1007/s12032-014-0264-5
Artigo de periodico
Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? (2013)
Habr-Gama, Angelita; Sabbaga, Jorge; Gama-Rodrigues, Joaquim; São Julião, Guilherme P.; Proscurshim, Igor; Aguilar, Patricia Bailão; Nadalin, Wladimir; Perez, Rodrigo O.
Fonte: Diseases of the Colon & Rectum. Unidade: FM
Assuntos: QUIMIOTERAPIA ADJUVANTE, NEOPLASIAS RETAIS (RADIOTERAPIA), ADENOCARCINOMA, DIAGNÓSTICO POR IMAGEM, TOMOGRAFIA COMPUTADORIZADA POR RAIOS X
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HABR-GAMA, Angelita et al. Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management?. Diseases of the Colon & Rectum, v. 56, n. 10, p. 1109-1117, 2013Tradução . . Disponível em: https://doi.org/10.1097/DCR.0b013e3182a25c4e. Acesso em: 25 out. 2025.
APA
Habr-Gama, A., Sabbaga, J., Gama-Rodrigues, J., São Julião, G. P., Proscurshim, I., Aguilar, P. B., et al. (2013). Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? Diseases of the Colon & Rectum, 56( 10), 1109-1117. doi:10.1097/DCR.0b013e3182a25c4e
NLM
Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Aguilar PB, Nadalin W, Perez RO. Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? [Internet]. Diseases of the Colon & Rectum. 2013 ; 56( 10): 1109-1117.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/DCR.0b013e3182a25c4e
Vancouver
Habr-Gama A, Sabbaga J, Gama-Rodrigues J, São Julião GP, Proscurshim I, Aguilar PB, Nadalin W, Perez RO. Watch and Wait Approach Following Extended Neoadjuvant Chemoradiation for Distal Rectal Cancer: Are We Getting Closer to Anal Cancer Management? [Internet]. Diseases of the Colon & Rectum. 2013 ; 56( 10): 1109-1117.[citado 2025 out. 25 ] Available from: https://doi.org/10.1097/DCR.0b013e3182a25c4e
Artigo de periodico
Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? (2013)
Braghiroli, Maria Ignez; Riechelmann,Rachel P.; Sabbaga, Jorge; Hoff, Paulo Marcelo Gehm
Fonte: Current colorectal cancer reports. Unidade: FM
Assuntos: NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA, ANTICORPOS MONOCLONAIS, QUIMIOTERAPIA (EFEITOS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRAGHIROLI, Maria Ignez et al. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same?. Current colorectal cancer reports, v. 9, n. 4, p. 317-325, 2013Tradução . . Disponível em: https://doi.org/10.1007/s11888-013-0187-0. Acesso em: 25 out. 2025.
APA
Braghiroli, M. I., Riechelmann, R. P., Sabbaga, J., & Hoff, P. M. G. (2013). Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? Current colorectal cancer reports, 9( 4), 317-325. doi:10.1007/s11888-013-0187-0
NLM
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2025 out. 25 ] Available from: https://doi.org/10.1007/s11888-013-0187-0
Vancouver
Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PMG. Do we need another antiangiogenesis agent for colorectal cancer: are bevacizumab and aflibercept the same? [Internet]. Current colorectal cancer reports. 2013 ; 9( 4): 317-325.[citado 2025 out. 25 ] Available from: https://doi.org/10.1007/s11888-013-0187-0
Artigo de periodico
Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer (2010)
Oliveira, Suilane Coelho Ribeiro; Machado, Karime Kalil; Sabbaga, Jorge; Hoff, Paulo M.
Fonte: Cancer Journal. Unidade: FM
Assuntos: ENDOTÉLIO VASCULAR, FATORES DE CRESCIMENTO (USO TERAPÊUTICO), NEOPLASIAS COLORRETAIS (EFEITOS DE DROGAS;QUIMIOTERAPIA), ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Suilane Coelho Ribeiro et al. Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer. Cancer Journal, v. 16, n. 3, p. 220-225, 2010Tradução . . Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/20526100. Acesso em: 25 out. 2025.
APA
Oliveira, S. C. R., Machado, K. K., Sabbaga, J., & Hoff, P. M. (2010). Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer. Cancer Journal, 16( 3), 220-225. doi:10.1097/PPO.0b013e3181ddc7c4
NLM
Oliveira SCR, Machado KK, Sabbaga J, Hoff PM. Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer [Internet]. Cancer Journal. 2010 ; 16( 3): 220-225.[citado 2025 out. 25 ] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20526100
Vancouver
Oliveira SCR, Machado KK, Sabbaga J, Hoff PM. Integration of Anti-Vascular Endothelial Growth Factor Therapies With Cytotoxic Chemotherapy in the Treatment of Colorectal Cancer [Internet]. Cancer Journal. 2010 ; 16( 3): 220-225.[citado 2025 out. 25 ] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20526100
Artigo de periodico
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy (2004)
Habr-Gama, Angelita; Perez, Rodrigo Oliva; Nadalin, Wladimir; Sabbaga, Jorge; Ribeiro Junior, Ulysses; Sousa Junior, Afonso Henrique Silva e; Campos, Fábio Guilherme; Kiss, Desidério Roberto; Gama-Rodrigues, Joaquim
Fonte: Annals of Surgery. Unidade: FM
Assuntos: NEOPLASIAS RETAIS (TERAPIA), NEOPLASIAS RETAIS (CIRURGIA), NEOPLASIAS RETAIS (QUIMIOTERAPIA), NEOPLASIAS RETAIS (RADIOTERAPIA), SEGUIMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HABR-GAMA, Angelita et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Annals of Surgery, v. 240, n. 4, p. 711-718, 2004Tradução . . Acesso em: 25 out. 2025.
APA
Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro Junior, U., Sousa Junior, A. H. S. e, et al. (2004). Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Annals of Surgery, 240( 4), 711-718.
NLM
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Junior U, Sousa Junior AHS e, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Annals of Surgery. 2004 ; 240( 4): 711-718.[citado 2025 out. 25 ]
Vancouver
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Junior U, Sousa Junior AHS e, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Annals of Surgery. 2004 ; 240( 4): 711-718.[citado 2025 out. 25 ]
Parte de monografia/livro
Câncer de mama: prevenção primária (2003)
Kemp, C.; Petti, Domingos Auricchio; Quadros, L. G. O.; Sabbaga, Jorge; Gebrim, L. H.; Assunção, M. C.; Ricci, M. D.
Fonte: Projeto Diretrizes. Unidade: FM
Assuntos: NEOPLASIAS, MAMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KEMP, C. et al. Câncer de mama: prevenção primária. Projeto Diretrizes. Tradução . São Paulo/Brasília: AMB & CFM, 2003. . . Acesso em: 25 out. 2025.
APA
Kemp, C., Petti, D. A., Quadros, L. G. O., Sabbaga, J., Gebrim, L. H., Assunção, M. C., & Ricci, M. D. (2003). Câncer de mama: prevenção primária. In Projeto Diretrizes. São Paulo/Brasília: AMB & CFM.
NLM
Kemp C, Petti DA, Quadros LGO, Sabbaga J, Gebrim LH, Assunção MC, Ricci MD. Câncer de mama: prevenção primária. In: Projeto Diretrizes. São Paulo/Brasília: AMB & CFM; 2003. [citado 2025 out. 25 ]
Vancouver
Kemp C, Petti DA, Quadros LGO, Sabbaga J, Gebrim LH, Assunção MC, Ricci MD. Câncer de mama: prevenção primária. In: Projeto Diretrizes. São Paulo/Brasília: AMB & CFM; 2003. [citado 2025 out. 25 ]

Unidades USP

ReP

Filtros

Tipo de material

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Título da fonte

Editora

Nome do evento

País de publicação

Indexado em